Related references
Note: Only part of the references are listed.Heart Disease and Stroke Statistics-2021 Update A Report From the American Heart Association
Salim S. Virani et al.
CIRCULATION (2021)
Impact of Geographic Region on the COMMANDER-HF Trial
Joao Pedro Ferreira et al.
JACC-HEART FAILURE (2021)
A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and Why
Mwango Kashoki et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
The 'Digital Twin' to enable the vision of precision cardiology
Jorge Corral-Acero et al.
EUROPEAN HEART JOURNAL (2020)
Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trials
Ruggero Lasala et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial
Pierpaolo Pellicori et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors JACC State-of-the-Art Review
Thomas A. Zelniker et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Keith T. Flaherty et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs
Janice Kim et al.
ONCOLOGIST (2020)
Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial Insights From COMMANDER HF
Jonathan W. Cunningham et al.
JACC-HEART FAILURE (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The 'Digital Twin' to enable the vision of precision cardiology
Jorge Corral-Acero et al.
EUROPEAN HEART JOURNAL (2020)
Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology
Rudolf A. de Boer et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Resolving genetic heterogeneity in cancer
Samra Turajlic et al.
NATURE REVIEWS GENETICS (2019)
Patient engagement at the heart of all European Society of Cardiology activities
Donna Fitzsimons
CARDIOVASCULAR RESEARCH (2019)
Surrogate endpoints in randomised controlled trials: a reality check
Shaji Kumar et al.
LANCET (2019)
Income level and inequality as complement to geographical differences in cardiovascular trials
Joao Pedro Ferreira et al.
AMERICAN HEART JOURNAL (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
S. D. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis
Huseyin Naci et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
4329Mega-studies in heart failure, effect dilution in examination of new therapies
O Cotter et al.
EUROPEAN HEART JOURNAL (2019)
Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols
Jay J. H. Park et al.
TRIALS (2019)
Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association
Sharon Cresci et al.
CIRCULATION-GENOMIC AND PRECISION MEDICINE (2019)
A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
Alyson Haslam et al.
EUROPEAN JOURNAL OF CANCER (2019)
Genetics and genomics of pulmonary arterial hypertension
Nicholas W. Morrell et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Evaluation of spin in oncology clinical trials
C. Wayant et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
2018 FDA drug approvals
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2019)
Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action
Antoni Bayes-Genis et al.
EUROPEAN HEART JOURNAL (2018)
Access versus evidence: The regulators' dilemma
Richard L. Schilsky
CLINICAL TRIALS (2018)
Medical Therapy for Heart Failure With Reduced Ejection Fraction
Stephen J. Greene et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Acute Heart Failure Deserves a Log-Scale Boost in Research Support Call for Multidisciplinary and Universal Actions
Alexandre Mebazaa
JACC-HEART FAILURE (2018)
A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics A Review
Julia A. Beaver et al.
JAMA ONCOLOGY (2018)
First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF
Michael R. Zile et al.
AMERICAN HEART JOURNAL (2018)
Exploring Meaningful Patient Engagement in ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness)
Madelaine Faulkner et al.
MEDICAL CARE (2018)
The complementary role of affect-based and cognitive heuristics to make decisions under conditions of ambivalence and complexity
Carlos Andres Trujillo
PLOS ONE (2018)
Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?
Joao Pedro Ferreira et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension
Edda Spiekerkoetter et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Improving Medication Adherence in Cardiometabolic Disease Practical and Regulatory Implications
Keith C. Ferdinand et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
Janet Woodcock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction
Sanjiv J. Shah
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH (2017)
Typical and atypical presenting symptoms of breast cancer and their associations with diagnostic intervals: Evidence from a national audit of cancer diagnosis
Minjoung Monica Koo et al.
CANCER EPIDEMIOLOGY (2017)
Composite End Points in Clinical Research A Time for Reappraisal
Paul W. Armstrong et al.
CIRCULATION (2017)
The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model
Randall J. Bateman et al.
ALZHEIMERS & DEMENTIA (2017)
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Gerasimos Filippatos et al.
EUROPEAN HEART JOURNAL (2016)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski et al.
EUROPEAN HEART JOURNAL (2016)
A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis
Nicolas Girerd et al.
EUROPEAN JOURNAL OF HEART FAILURE (2016)
Natriuretic Peptides, 6-Min Walk Test, and Quality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials
Joao Pedro Ferreira et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Precision or imprecision medicine?
Lisa Hutchinson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Medication-related burden and patients' lived experience with medicine: a systematic review and metasynthesis of qualitative studies
Mohammed A. Mohammed et al.
BMJ OPEN (2016)
Continuous patient engagement in cardiovascular disease clinical comparative effectiveness research
Joseph Vandigo et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2016)
Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400
Roy S. Herbst et al.
CLINICAL CANCER RESEARCH (2015)
Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
Shany Koren et al.
MOLECULAR CELL (2015)
Oral Anticancer Medication Adherence, Toxicity Reporting, and Counseling: A Study Comparing Health Care Providers and Patients
Sonal Gandhi et al.
JOURNAL OF ONCOLOGY PRACTICE (2015)
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial
Marc A. Pfeffer et al.
CIRCULATION (2015)
Right to Try laws
Colin B. Begg et al.
CLINICAL TRIALS (2014)
American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
Lee M. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Patient Reported Outcomes (PROs) in Clinical Trials: Is 'In-Trial' Guidance Lacking? A Systematic Review
Derek G. Kyte et al.
PLOS ONE (2013)
Progression-Free Survival: Meaningful or Simply Measurable?
Christopher M. Booth et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The Lost Decade of Nesiritide
Eric J. Topol
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Effect of Nesiritide in Patients with Acute Decompensated Heart Failure
C. M. O'Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The Impact of Perceived Adverse Effects on Medication Changes in Heart Failure Patients
Ruth H. E. De Smedt et al.
JOURNAL OF CARDIAC FAILURE (2010)
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
A. D. Barker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Short-term risk of death after treatment with nesiritide for decompensated heart failure - A pooled analysis of randomized controlled trials
JD Sackner-Bernstein et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure
JD Sackner-Bernstein et al.
CIRCULATION (2005)
Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure.
WS Colucci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
